© 2004 by Oxford University Press
© 2004 Oxford University Press
REVIEW |
Ductal Carcinoma In Situ, Complexities and Challenges
Affiliation of authors: Cancer Therapeutics Branch, National Cancer Institute, Bethesda, MD
Correspondence to: Sandra M. Swain, MD, Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, OHHS, National Naval Medical Center, Bldg. 8, Rm. 5101, 8901 Wisconsin Ave., Bethesda, MD 20889-5105 (e-mail: swains{at}mail.nih.gov)
The incidence of ductal carcinoma in situ (DCIS), a noninvasive form of breast cancer, has increased markedly in recent decades, and DCIS now accounts for approximately 20% of breast cancers diagnosed by mammography. Laboratory and patient data suggest that DCIS is a precursor lesion for invasive cancer. The appropriate classification of DCIS has provoked much debate; a number of classification systems have been developed, but there is a lack of uniformity in the diagnosis and prognostication of this disease. Further investigation of molecular markers should improve the classification of DCIS and our understanding of its relationship to invasive disease. Controversy also exists with regard to the optimal management of DCIS patients. In the past, mastectomy was the primary treatment for patients with DCIS, but as with invasive cancer, breast-conserving surgery has become the standard approach. Three randomized trials have reported a statistically significant decrease in the risk of recurrence with radiation therapy in combination with lumpectomy compared with lumpectomy alone, but there was no survival advantage with the addition of radiotherapy. Two randomized trials have suggested an additional benefit, in terms of recurrence, with the addition of adjuvant tamoxifen therapy, although in one trial the benefit was not statistically significant. Current data suggest that tamoxifen use should be restricted to patients with estrogen receptor–positive DCIS. Neither trial demonstrated a survival benefit with adjuvant tamoxifen. Ongoing and recently completed studies should provide information on outcomes in patients treated with lumpectomy alone and on the effectiveness of aromatase inhibitors as an alternative to tamoxifen.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Raza, M. Vallejo, S. A. Chikarmane, and R. L. Birdwell Pure Ductal Carcinoma in Situ: A Range of MRI Features Am. J. Roentgenol., September 1, 2008; 191(3): 689 - 699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vincent-Salomon, C. Lucchesi, N. Gruel, V. Raynal, G. Pierron, R. Goudefroye, F. Reyal, F. Radvanyi, R. Salmon, J.-P. Thiery, et al. Integrated Genomic and Transcriptomic Analysis of Ductal Carcinoma In situ of the Breast Clin. Cancer Res., April 1, 2008; 14(7): 1956 - 1965. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dawood, K. Broglio, A. M. Gonzalez-Angulo, S.-W. Kau, W. Yang, C. Albarracin, F. Meric, G. Hortobagyi, and R. Theriault Development of New Cancers in Patients with DCIS: The M.D. Anderson Experience Ann. Surg. Oncol., January 1, 2008; 15(1): 244 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Harris, H. Fritsche, R. Mennel, L. Norton, P. Ravdin, S. Taube, M. R. Somerfield, D. F. Hayes, and R. C. Bast Jr American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer J. Clin. Oncol., November 20, 2007; 25(33): 5287 - 5312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mimeault and S. K. Batra Interplay of distinct growth factors during epithelial mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies Ann. Onc., October 1, 2007; 18(10): 1605 - 1619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. B. Julian, S. R. Land, V. Fourchotte, S. R. Haile, E. R. Fisher, E. P. Mamounas, J. P. Costantino, and N. Wolmark Is Sentinel Node Biopsy Necessary in Conservatively Treated DCIS? Ann. Surg. Oncol., August 1, 2007; 14(8): 2202 - 2208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Garrido-Laguna, O. Fernandez Hidalgo, J. Garcia Foncillas, D. Gyorki, B. Mann, F. Frauscher, K. J. Sweeney, V. Sacchini, I. Nash, P. M. Marcus, et al. MRI Evaluation of Breast Cancer N. Engl. J. Med., July 12, 2007; 357(2): 191 - 193. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Itoh, C. M. Nelson, C. A. Myers, and M. J. Bissell Rap1 Integrates Tissue Polarity, Lumen Formation, and Tumorigenic Potential in Human Breast Epithelial Cells Cancer Res., May 15, 2007; 67(10): 4759 - 4766. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Farnie, R. B. Clarke, K. Spence, N. Pinnock, K. Brennan, N. G. Anderson, and N. J. Bundred Novel Cell Culture Technique for Primary Ductal Carcinoma In Situ: Role of Notch and Epidermal Growth Factor Receptor Signaling Pathways J Natl Cancer Inst, April 18, 2007; 99(8): 616 - 627. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Steinman, J. Wang, P. Bourne, Q. Yang, and P. Tang Expression of Cytokeratin Markers, ER-alpha, PR, HER-2/neu, and EGFR in Pure Ductal Carcinoma In Situ (DCIS) and DCIS with Co-existing Invasive Ductal Carcinoma (IDC) of the Breast Ann. Clin. Lab. Sci., January 1, 2007; 37(2): 127 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Tang, X. Wang, L. Schiffhauer, J. Wang, P. Bourne, Q. Yang, A. Quinn, and S. I. Hajdu Relationship between Nuclear Grade of Ductal Carcinoma in situ and Cell Origin Markers. Ann. Clin. Lab. Sci., December 1, 2006; 36(1): 16 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. I.J. Wildschut, T.J. Peters, and C. P. Weiner Screening in women's health, with emphasis on fetal Down's syndrome, breast cancer and osteoporosis Hum. Reprod. Update, September 1, 2006; 12(5): 499 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Wood, A. L. Usborne, M. F. Starost, R. P. Tarara, L. R. Hill, L. M. Wilkinson, K. R. Geisinger, E. A. Feiste, and J. M. Cline Hyperplastic and neoplastic lesions of the mammary gland in macaques. Vet. Pathol., July 1, 2006; 43(4): 471 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Fackler, K. Malone, Z. Zhang, E. Schilling, E. Garrett-Mayer, T. Swift-Scanlan, J. Lange, R. Nayar, N. E. Davidson, S. A. Khan, et al. Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin. Cancer Res., June 1, 2006; 12(11): 3306 - 3310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Tang, X. Wang, L. Schiffhauer, J. Wang, P. Bourne, Q. Yang, A. Quinn, and S. Hajdu Expression Patterns of ER-{alpha}, PR, HER-2/neu, and EGFR in Different Cell Origin Subtypes of High Grade and Non-High Grade Ductal Carcinoma In Situ. Ann. Clin. Lab. Sci., March 1, 2006; 36(2): 137 - 143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Murata, S. L. Kominsky, M. Vali, Z. Zhang, E. Garrett-Mayer, D. Korz, D. Huso, S. D. Baker, J. Barber, E. Jaffee, et al. Ductal Access for Prevention and Therapy of Mammary Tumors Cancer Res., January 15, 2006; 66(2): 638 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Arpino, R. Laucirica, and R. M. Elledge Premalignant and In Situ Breast Disease: Biology and Clinical Implications Ann Intern Med, September 20, 2005; 143(6): 446 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Bertagnolli Surgical Prevention of Cancer J. Clin. Oncol., January 10, 2005; 23(2): 324 - 332. [Abstract] [Full Text] [PDF]
|
|